Clinical-radiomic features predict survival in patients with extranodal nasal-type natural killer/T cell lymphoma-Reference-Cited by-同舟云学术

Clinical-radiomic features predict survival in patients with extranodal nasal-type natural killer/T cell lymphoma

Published:2022-08-26 Issue:3 Volume:5 Page:200-209
ISSN:2520-8985
Container-title:Chinese Journal of Academic Radiology
language:en
Short-container-title:Chin J Acad Radiol

Author:

Wang Xinyan,Qu Xiaoxia,Xia Yuwei,Wei Liqiang,Yang Jing,Guo Na,Zuo Panli,Wang Liang,Xian Junfang^ORCID

Funder

Beijing Municipal Administration of Hospitals’ Ascent Plan

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support

National Key Technology Research and Development Program of the Ministry of Science and Technology of China

National Natural Science Foundation of China

the Open Research Fund from Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University, and Capital Medical University

Beijing Municipal Administration of Hospitals’ Youth Program to Liang Wang

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s42058-022-00100-x.pdf

Reference27 articles.

1. Xiong J, Zhao W. What we should know about natural killer/T-cell lymphomas. Hematol Oncol. 2019;37(Suppl 1):75–81. https://doi.org/10.1002/hon.2588.

2. Su Y, Wang P, Chang H, et al. Extranodal NK/T-cell lymphoma, nasal type: clinical features, outcome, and prognostic factors in 101 cases. Eur J Haematol. 2018;101:379–88. https://doi.org/10.1111/ejh.13126.

3. Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131:2528–40. https://doi.org/10.1182/blood-2017-12-791418.

4. Lim SH, Hong JY, Lim ST, et al. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017;28:2199–205. https://doi.org/10.1093/annonc/mdx316.

5. Chen S, Yang Y, Qi S, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35:130–42. https://doi.org/10.1038/s41375-020-0791-3.